Gentile V, Brunetto D, Leo I, Bonetti S, Verrotti A, Franzoni E
Child Neuropsychiatry Unit, Paediatric Department, University of Bologna, Italy.
Neuropediatrics. 2010 Dec;41(6):270-2. doi: 10.1055/s-0031-1273704. Epub 2011 Mar 28.
The International League Against Epilepsy (ILAE) classification recognizes 2 forms of myoclonic epilepsy with a good prognosis: benign myoclonic epilepsy of infancy (BMEI) and juvenile myoclonic epilepsy (JME); recent studies confirm the efficacy of levetiracetam (LEV) in treating idiopathic generalized epilepsies (IGE) in patients with myoclonic seizures. We report a girl referred to our Child Neuropsychiatry Unit at age 9 years because of massive myoclonic jerks, previously diagnosed as tics. Neuropsychological examination evidenced mild cognitive impairment. The clinical and electroencephalogram (EEG) data led to diagnosis of BMEI with late presentation. A dramatic suppression of interictal and ictal epileptiform activity was achieved after only one intake of LEV. Another neuropsychological examination after 6 months of treatment showed performance improvement probably related to EEG modifications. LEV may be suitable for the first-line treatment of myoclonic idiopathic seizures.
国际抗癫痫联盟(ILAE)分类法确认了两种预后良好的肌阵挛性癫痫:婴儿良性肌阵挛性癫痫(BMEI)和青少年肌阵挛性癫痫(JME);近期研究证实左乙拉西坦(LEV)在治疗有肌阵挛发作的特发性全身性癫痫(IGE)患者中具有疗效。我们报告一名9岁女孩,因大量肌阵挛性抽搐转诊至我们儿童神经精神病科,此前被诊断为抽动症。神经心理学检查显示有轻度认知障碍。临床和脑电图(EEG)数据诊断为迟发性BMEI。仅服用一次LEV后,发作间期和发作期癫痫样活动就得到了显著抑制。治疗6个月后的另一次神经心理学检查显示,其表现有所改善,这可能与脑电图改变有关。LEV可能适用于肌阵挛性特发性癫痫发作的一线治疗。